Xylem Inc. (NYSE:XYL) does about 867.42K shares in volume on a normal day but saw 11668570 shares change hands in Monday trading. The company now has a market cap of 18.02B USD. Its current market price is $101.42, marking a decrease of -7.95% compared to the previous close of $110.18. The 52 week high reached by this stock is $118.58 whilst the lowest price level in 52 weeks is $72.08. The script in recent trading has seen the stock touch a high of $101.90 and a low of $97.29.
Xylem Inc. (XYL) has a 20-day trading average at $111.20 and the current price is -14.47% off the 52-week high compared with 40.70% distance from its 52-week low. The 50-day simple moving average of the closing price is $111.35 and its 200-day simple moving average is $94.21. If we look at the stock’s price movements over the week, volatility stands at 3.19%, which decreases to 2.45% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 33.47 to suggest the stock is neutral.
The consensus objective for the share price is $110.67, suggesting that the stock has a potential upside of 8.36% over the period. The median price target is 9.85% away from the current levels at $112.50.
Stifel also downgraded the stock to “Hold” from Buy on December 19, 2022 at a price target of $113-$115. Atlantic Equities upgraded its price target at $110-$129.
The current price level is -9.19%, -9.03%, and 7.74% away from its SMA20, SMA50, and SMA200 respectively, with the XYL price moving above the 50-day SMA on January 23. Xylem Inc. (XYL) stock is down -13.26% over the week and -6.34% over the past month. Its price is -8.28% year-to-date and -4.79% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of $0.79 above consensus estimates by $0.13. The company’s next earnings report is expected on 05/02/2023, with forecasts estimating quarterly EPS at $0.79 and $2.71 for whole year. XYL’s earnings per share are forecast to grow by 8.80% this year and 16.60% over next year. Expected sales for next quarter are $1.32 billion, which analysts say will come at $5.43 billion for the current fiscal year and next year at $5.65 billion. In addition, estimates put the company’s current quarterly revenue at an average of $1.41 billion.
Its 12-month price target is $112.50. To reach the target analysts have set, the stock logically needs to grow 8.36 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $92.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $129.00.
Outstanding shares total 180.20M with insiders holding 0.82% of the shares and institutional holders owning 92.02% of the company’s common stock. The company has a return on investment of 8.90% and return on equity of 9.90%. The price to earnings ratio (P/E ratio) amounts to 57.56 while the forward price to earnings ratio is 32.09. The beta has a value of 1.09. Price to book ratio is 5.68 and price to sales ratio is 3.38.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has added its position in Xylem Inc. (XYL) to 5,482,567 shares, mirroring a recent increase by 1.15%. Vanguard Total Stock Market Index added 62195.0 shares of Xylem Inc. common stock bringing its total worth to about $606.21 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Mid Cap Index Fund, which sold off 18569.0 shares to end up with 4,197,225 shares worth $464.09 million. Vanguard 500 Index Fund raise their holdings by 0.94% in the company over the course of the most recent quarter. It now holds a 2.31% position in Xylem Inc. thanks to 4.17 million shares amounting to $460.62 million.